US23284P1030 - Common Stock
A little-known biotech company, Cyteir Therapeutics Inc., is about to notch its best day ever — on the back of plans to dissolve the company.
BofA Securities has downgraded Cyteir Therapeutics (CYT) to neutral from buy citing the company's recent decision on a pipeline prioritization to focus on combination therapies.
Cyteir Therapeutics (CYT) will prioritize clinical development of CYT-0851 and reduce its workforce as part of the prioritization. Read more here.